ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Adolescent Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,542Medicare Part D Prescriptions Filled, Including Refills
$700K Total Retail Price of All Prescriptions
332 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
93% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
SIMVASTATIN 472 431
NEXIUM 423 349
GLYBURIDE-METFORMIN HCL 281 245 R
AMOX TR-POTASSIUM CLAVULANATE 219 172
LISINOPRIL 206 179
AMLODIPINE BESYLATE 191 177
METOPROLOL SUCCINATE 172 153
HYDROCODONE-ACETAMINOPHEN 168 127 S3
METOPROLOL TARTRATE 159 143
NAPROXEN 157 112
ATORVASTATIN CALCIUM 139 124
OMEPRAZOLE 138 107
LOSARTAN-HYDROCHLOROTHIAZIDE 133 132
FUROSEMIDE 130 120
CLOPIDOGREL 107 95
TAMSULOSIN HCL 102 96
LEVOTHYROXINE SODIUM 101 74
SULFAMETHOXAZOLE-TRIMETHOPRIM 101 85
ACTOS 96 76
METFORMIN HCL 96 81
HYDROCODONE BIT-IBUPROFEN 94 73 S3
LOSARTAN POTASSIUM 88 80
NYSTATIN-TRIAMCINOLONE 88 78
VOLTAREN 83 77
NABUMETONE 82 70
AZITHROMYCIN 78 62
PLAVIX 75 71
CRESTOR 71 55
CIPROFLOXACIN HCL 71 54
GABAPENTIN 68 53
LEVOFLOXACIN 67 57
DIOVAN HCT 66 62
DONEPEZIL HCL 66 66
INSULIN SYRINGE 66 52
SERTRALINE HCL 64 57
ENALAPRIL MALEATE 64 51
TRIAMCINOLONE ACETONIDE 60 54
VYTORIN 58 53
POTASSIUM CHLORIDE 58 49
DILTIAZEM HCL 58 57
ALLOPURINOL 56 49
DIOVAN 53 38
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.